Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer | CLINICAL LUNG CANCER |